Satsuma Pharmaceuticals, Inc. (“Satsuma”) (Nasdaq: STSA) announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. (TSE: 2395, “SNBL”) for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right (“CVR”) of up to $5.77 per share. The CVR is payable pursuant to the future sale, license, or any other monetization events related to STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.
Read the full article: SNBL to Acquire Satsuma Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2023/04/16/2647523/0/en/SNBL-to-Acquire-Satsuma-Pharmaceuticals.html